84 related articles for article (PubMed ID: 15286695)
1. Bone metabolism in patients more than five years after bone marrow transplantation.
Kerschan-Schindl K; Mitterbauer M; Füreder W; Kudlacek S; Grampp S; Bieglmayer C; Fialka-Moser V; Pietschmann P; Kalhs P
Bone Marrow Transplant; 2004 Sep; 34(6):491-6. PubMed ID: 15286695
[TBL] [Abstract][Full Text] [Related]
2. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
[TBL] [Abstract][Full Text] [Related]
3. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation.
Kananen K; Volin L; Tähtelä R; Laitinen K; Ruutu T; Välimäki MJ
Bone Marrow Transplant; 2002 Jan; 29(1):33-9. PubMed ID: 11840142
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin.
Välimäki MJ; Kinnunen K; Volin L; Tähtelä R; Löyttyniemi E; Laitinen K; Mäkelä P; Keto P; Ruutu T
Bone Marrow Transplant; 1999 Feb; 23(4):355-61. PubMed ID: 10100579
[TBL] [Abstract][Full Text] [Related]
5. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
[TBL] [Abstract][Full Text] [Related]
6. Decreased bone mineral density is common after autologous blood or marrow transplantation.
Schimmer AD; Mah K; Bordeleau L; Cheung A; Ali V; Falconer M; Trus M; Keating A
Bone Marrow Transplant; 2001 Aug; 28(4):387-91. PubMed ID: 11571512
[TBL] [Abstract][Full Text] [Related]
7. [Bone mass, bone metabolism, and prevalence of spinal fractures in recipients of allogenic bone marrow transplantation for leukemia].
Letizia C; Celi M; Iori AP; Verrelli C; Caliumi C; Diacinti D; Arcese W; D'Erasmo E
Ann Ital Med Int; 2004; 19(3):175-83. PubMed ID: 15529945
[TBL] [Abstract][Full Text] [Related]
8. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
9. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
[TBL] [Abstract][Full Text] [Related]
10. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
11. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
12. Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation.
Lee WY; Baek KH; Rhee EJ; Tae HJ; Oh KW; Kang MI; Lee KW; Kim SW; Kim CC; Oh ES
Bone Marrow Transplant; 2004 Jul; 34(1):89-94. PubMed ID: 15170175
[TBL] [Abstract][Full Text] [Related]
13. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
Morabito N; Russo GT; Gaudio A; Lasco A; Catalano A; Morini E; Franchina F; Maisano D; La Rosa M; Plota M; Crifò A; Meo A; Frisina N
Bone; 2007 Jun; 40(6):1588-94. PubMed ID: 17412659
[TBL] [Abstract][Full Text] [Related]
14. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density in children with thalassaemia major: determining factors and effects of bone marrow transplantation.
Leung TF; Hung EC; Lam CW; Li CK; Chu Y; Chik KW; Shing MM; Lee V; Yuen PM
Bone Marrow Transplant; 2005 Aug; 36(4):331-6. PubMed ID: 15968288
[TBL] [Abstract][Full Text] [Related]
16. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
18. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients.
Marcén R; Caballero C; Uriol O; Fernández A; Villafruela JJ; Pascual J; Martins J; Rodriguez N; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2256-8. PubMed ID: 17889156
[TBL] [Abstract][Full Text] [Related]
20. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases.
Bai XL; Liang TB; Wu LH; Li DL; Geng L; Wang WL; Shen Y; Zhang M; Zheng SS
Transplant Proc; 2007 Dec; 39(10):3182-5. PubMed ID: 18089348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
